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Background/AimsIt has been suggested that, in HIV–HCV co-infected patients, co-
infections with other viruses may affect the response to HCV therapy. We aimed to
assess the prevalence of GBV-C, SEN-V and occult HBV infections, their impact on
HCV and HIV infections and on the response to HCV therapy in HIV–HCV co-
infected patients. Methods Three-hundred and sixty eight patients were tested
before starting interferon–ribavirin for the presence of occult hepatitis B DNA, GBV-
C RNA and SEN-V DNA by using real time PCR. Clinical, immunological, virological,
histological characteristics and response to HCV therapy were compared according
to the presence or not of each viral co-infection. Results HBV DNA, GBV-C RNA and
SEN-V DNA were found in 5 (1.4%, CI95%: 0.2–2.4%), 104 (29.9%, CI95%:
25.1–34.7%) and 209 patients (57.9%, CI95%: 52.8–63.0%), respectively. GBV-C
positive patients had significantly higher CD4 count at baseline, during and after
HCV therapy, even after stratification on antiretroviral treatment. No other
significant difference was observed according to the presence or not of GBV-C or
SEN-V co-infection, in particular regarding virological responses to HCV
combination therapy. Conclusions There is no reason to withhold HCV therapy in
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